NasdaqGM:HROWPharmaceuticals
Harrow Refocuses After ImprimisRx Exit As New CCO Takes Charge
ImprimisRx, a division of Harrow (NasdaqGM:HROW), has exited the California market following the settlement of regulatory matters.
The company described the move as a voluntary decision tied to the resolution of those regulatory issues.
Harrow has promoted Patrick W. Sullivan to Chief Commercial Officer, expanding its senior leadership team.
Harrow, through its ImprimisRx division, focuses on ophthalmic pharmaceuticals, a segment that often sits at the intersection of clinical needs and...